Do Not Split Guanfacine Extended-Release 3 mg Tablets
Guanfacine extended-release tablets should never be split, crushed, or broken, as this destroys the extended-release mechanism and can result in uncontrolled rapid drug release leading to potentially dangerous overdose.
Why Splitting is Contraindicated
Extended-release formulations are specifically engineered to deliver medication gradually over 24 hours. When you split an extended-release guanfacine tablet:
- The controlled-release coating is destroyed, causing immediate release of the full dose rather than gradual delivery 1
- Overdose risk increases significantly due to rapid absorption of medication designed for slow release 1
- Cardiovascular effects are amplified, as guanfacine already causes decreases in heart rate and blood pressure 2. Rapid release could cause severe bradycardia and hypotension
Clinical Evidence on Extended-Release Formulations
The FDA labeling and clinical guidelines consistently emphasize that extended-release guanfacine (GXR) has different pharmacokinetics than immediate-release formulations and is not substitutable on a mg-for-mg basis 3. The extended-release formulation achieves:
- Peak plasma concentrations over 1-4 hours with controlled absorption 4
- Steady-state levels within 4 days 5
- Elimination half-life of approximately 17 hours 5
Splitting destroys this carefully designed pharmacokinetic profile.
Additional Safety Concerns
Beyond the extended-release issue, tablet splitting generally creates problems:
- Weight variability between split portions can reach 21.3% of total content with hand splitting 6
- Loss of drug stability when protective coatings are breached 1
- Many elderly patients physically cannot split tablets accurately 1
The Correct Approach
If dose adjustment is needed:
- Use the appropriate commercially available strength (1 mg or 3 mg tablets are available) 7
- Start at lower doses (1 mg) and titrate upward as clinically indicated 5
- Never attempt to create intermediate doses by splitting extended-release tablets
The guideline evidence is clear that guanfacine should be tapered rather than abruptly discontinued to avoid rebound hypertension 2, but this refers to dose reduction using intact lower-strength tablets, not splitting.